Breakthrough drug trial offers hope for kids with devastating genetic epilepsy
NCT ID NCT07019922
Summary
This Phase 3 clinical trial is testing whether a new drug called elsunersen can reduce seizure frequency in children with a rare, severe form of genetic epilepsy called SCN2A developmental and epileptic encephalopathy. The study will enroll 50 pediatric participants who began having seizures before 3 months of age and currently experience at least 4 countable seizures per month. Researchers will compare the drug against a sham procedure to determine if it safely reduces seizures over 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis Research Site
RECRUITINGSan Diego, California, 92123, United States
-
Praxis Research Site
RECRUITINGChicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.